{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-002543","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.972424+00:00","generated_at":"2026-06-27T19:31:18.668012+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kiniksa reports ~$182M year-end cash sufficient into 2024; mavrilimumab Phase 3 fails; pipeline updates","bullets":["Preliminary year-end 2021 cash, cash equivalents and short-term investments of ~$182M (unaudited), expected to fund operations into 2024.","Mavrilimumab Phase 3 in COVID-19 ARDS did not meet primary endpoint; company evaluating next steps.","Full-year 2022 ARCALYST net revenue guidance to be provided with Q4 and full-year 2021 financial results.","Vixarelimab Phase 2b data in prurigo nodularis expected in second half of 2022.","KPL-404 Phase 2 trial in rheumatoid arthritis now enrolling and dosing patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-002543","json":"https://secwatch.observer/filing/0001104659-22-002543.json","markdown":"https://secwatch.observer/filing/0001104659-22-002543.md","text":"https://secwatch.observer/filing/0001104659-22-002543.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465922002543/0001104659-22-002543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465922002543/tm222297d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:31:18.668012+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}